NOD2 and osteosarcoma: Specifically, NOD2 agonist mifamurtide certainly represents the most important compound to have been granted with marketing authorization by the European Medicine Agency for treating osteosarcoma in combination with other chemotherapeutics, following complete surgical removal of a primary tumor.